Clinical Trials Update from NCI, October 2021

National Cancer Institute banner

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
Illustration of stage 3A lung cancer  

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

Atezolizumab (Tecentriq) is now the first immunotherapy approved by the Food and Drug Administration for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010.

Antibody-drug conjugate mechanism of action  

Enhertu May Be Preferred Therapy for Some with Metastatic Breast Cancer

In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) greatly improved progression-free survival compared with trastuzumab emtansine (Kadcyla), new study results show.

Surgery to remove melanoma  

Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning

Clinical trial results show people who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage 2 melanomas were less likely to have the cancer come back than those who received no treatment after surgery.


Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer

In a large clinical trial, people with HR-positive, HER2-negative metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their first treatment lived about 1 year longer than women treated with letrozole only.

Clinical Trials Information for Patients and Caregivers

Scientific Review

This page explains how clinical trials undergo extensive scientific review before people are enrolled and while the study is conducted. It introduces the various groups that review trials and monitor their progress.


Ending Trials Early

Sometimes clinical trials are stopped early, before the planned treatment period has been completed. This page explains several reasons why a trial might end early.

Search for a clinical trial  

Find NCI-Supported Clinical Trials

Use our search form to find a clinical trial or other research study that may be right for you or a loved one.

NCI-Supported Clinical Trials That Are Recruiting Patients 

Reducing Peripheral Neuropathy in Black Patients with Breast Cancer

This phase 2 trial will determine whether treatment with the drug docetaxel (Taxotere) leads to fewer or less severe cases of peripheral neuropathy than treatment with paclitaxel (Abraxane) in Black people with early-stage breast cancer. Doctors will also assess the relationship between certain genetic signatures and the likelihood of peripheral neuropathy caused by paclitaxel.


Testing Combination Therapy for Virus-Related Cancers

This phase 1 trial will test pomalidomide (Pomalyst) combined with the immunotherapy drug nivolumab (Opdivo) in people with cancers caused by viruses. Doctors will assess the safety and determine the best dose of the combination.


Preventing Liver Cancer in Patients with Cirrhosis


This phase 2 trial will test how well the drug simvastatin (Zocor) works in preventing liver cancer in people with cirrhosis of the liver. Simvastatin is commonly used to treat high cholesterol and triglycerides. Doctors will assign people with advanced liver cirrhosis by chance to receive either simvastatin or placebo for 6 months to see if the drug protects them from developing liver cancer.